Genmab Reaches Third Milestone in Lundbeck Collaboration

Company Announcement

• Third pre-clinical milestone met in Lundbeck collaboration


• [Eur]1 million milestone payment to Genmab

COPENHAGEN, Denmark, Dec. 13, 2012 (GLOBE NEWSWIRE) -- Genmab A/S ( GEN.CO ) announced today it had reached the third pre-clinical milestone in the collaboration with H. Lundbeck A/S, triggering a [Eur]1 million payment (approximately DKK 7.5 million). Under the collaboration with Lundbeck, Genmab creates novel human antibodies to three central nervous system (CNS) targets identified by Lundbeck and Lundbeck has access to Genmab's antibody creation and development capabilities.